Emerging treatments in type 2 diabetes: focus on canagliflozin
Marek Rosiak,1,2 Susanna Grzeszczak,2 Dariusz A Kosior,2,3 Marek Postuła1,2 1Department of Cardiology and Hypertension, Central Clinical Hospital, the Ministry of the Interior, Warsaw, Poland; 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland; 3Mossakowski M...
Saved in:
Main Authors: | Rosiak M (Author), Grzeszczak S (Author), Kosior DA (Author), Postuła M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014) -
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014) -
Canagliflozin: a novel treatment option for type 2 diabetes
by: Dietrich E, et al.
Published: (2013) -
Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018) -
Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016)